These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 16219576)

  • 1. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions.
    Mutis T; Aarts-Riemens T; Verdonck LF
    Haematologica; 2005 Oct; 90(10):1389-95. PubMed ID: 16219576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
    Xia G; Kovochich M; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
    Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
    Yang K; Fan ZP; Liu QF; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor regulatory T cells identified by FoxP3 expression but also by the membranous CD4+CD127low/neg phenotype influence graft-versus-tumor effect after donor lymphocyte infusion.
    Hicheri Y; Bouchekioua A; Hamel Y; Henry A; Rouard H; Pautas C; Beaumont JL; Kuentz M; Cordonnier C; Cohen JL; Maury S
    J Immunother; 2008; 31(9):806-11. PubMed ID: 18833007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation.
    Meignin V; Peffault de Latour R; Zuber J; Régnault A; Mounier N; Lemaître F; Dastot H; Itzykson R; Devergie A; Cumano A; Gluckman E; Janin A; Bandeira A; Socié G
    Exp Hematol; 2005 Aug; 33(8):894-900. PubMed ID: 16038781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of the CD4+CD25high T-regulatory cells in recipients and their corresponding donors to acute GVHD.
    Zhai Z; Sun Z; Li Q; Zhang A; Liu H; Xu J; Xu X; Geng L; Harris D; Hu S; Wang Y
    Transpl Int; 2007 May; 20(5):440-6. PubMed ID: 17313446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit.
    Tanaka J; Sugita J; Kato N; Toubai T; Ibata M; Shono Y; Ota S; Kondo T; Kobayashi T; Kobayashi M; Asaka M; Imamura M
    Exp Hematol; 2007 Oct; 35(10):1562-6. PubMed ID: 17681668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
    Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
    Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Wolf D; Wolf AM; Fong D; Rumpold H; Strasak A; Clausen J; Nachbaur D
    Transplantation; 2007 Apr; 83(8):1107-13. PubMed ID: 17452902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.